<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HEBA281FC9219453EA04D2001A60DDEA4" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4449 IH: Pharmaceutical Security Production Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4449</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230630">June 30, 2023</action-date><action-desc><sponsor name-id="T000486">Mr. Torres of New York</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To establish the Commission on Strengthening the Domestic Pharmaceutical Supply Chain, and for other purposes.</official-title></form><legis-body id="HB455ED98CFDA443EB7ECC4E26E484F80" style="OLC"> 
<section id="H84A95BBB12E04429A03435A9208212B0" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Pharmaceutical Security Production Act</short-title></quote>.</text></section> <section id="H0262C8428A3A4E3F87F963111D968078"><enum>2.</enum><header>Commission on Strengthening the Domestic Pharmaceutical Supply Chain</header> <subsection id="H4C39557915064F0BB6BB424A3B866893"><enum>(a)</enum><header>Establishment</header><text display-inline="yes-display-inline">There is established a commission to be known as the <quote>Commission on Strengthening the Domestic Pharmaceutical Supply Chain</quote> (in this section referred to as the <quote>Commission</quote>) to assess the current security and vulnerabilities of the United States pharmaceutical supply chain.</text></subsection> 
<subsection id="H653F0AA035474B5484D9FA290BD93383"><enum>(b)</enum><header>Duties</header><text>The duties of the Commission are the following:</text> <paragraph id="H02493403F4AD46818BCCDA03DB25F968"><enum>(1)</enum><text display-inline="yes-display-inline">Determine concrete timelines and metrics for success for the Pharmaceutical Manufacturing in America program of the Biomedical Advanced Research and Development Authority to produce advanced pharmaceutical ingredients for medicines included in the essential medicines list.</text></paragraph> 
<paragraph id="H2ECDF87600A94375ABDBDF94B522BD17"><enum>(2)</enum><text display-inline="yes-display-inline">Evaluate and identify vulnerabilities in the existing United States pharmaceutical supply chain that could be exploited by foreign adversaries and nonstate actors.</text></paragraph> <paragraph id="H4CBABDD7D1CF40C2B063B822E87A2C91"><enum>(3)</enum><text display-inline="yes-display-inline">Review and propose solutions to strengthen the domestic pharmaceutical manufacturing workforce to support increased production of advanced pharmaceutical ingredients and finished drugs.</text></paragraph> 
<paragraph id="H3A071234D3674A02A24131A75B4598B1"><enum>(4)</enum><text display-inline="yes-display-inline">Assess how Federal health care programs (as defined in section 1128B(f) of the Social Security Act (42 U.S.C. 1320aâ€“7b(f))), the program established under <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/89">chapter 89</external-xref> of title 5, United States Code, and provider facilities can be used to create a viable financial market for domestically made advanced pharmaceutical ingredients and finished drug products.</text></paragraph> <paragraph id="HDB3428016AA74A1A9B968920E34A0C57"><enum>(5)</enum><text display-inline="yes-display-inline">Review the successes and failures of Operation Warp Speed and determine if any best practices for public-private partnerships can be used to bolster domestic manufacturing of advanced pharmaceutical ingredients and finished drug products.</text></paragraph> 
<paragraph id="H5866448E646A4720B3CC85BFF13522A6"><enum>(6)</enum><text display-inline="yes-display-inline">Estimate the Federal funding necessary to catalyze and strengthen domestic pharmaceutical manufacturing.</text></paragraph> <paragraph id="H07D5E6A6B6B84EE3BE034BFC689ACB38"><enum>(7)</enum><text display-inline="yes-display-inline">Identify facilities throughout the United States that can be repurposed to produce advanced pharmaceutical ingredients, especially advanced pharmaceutical ingredients listed on the essential medicines list.</text></paragraph> 
<paragraph id="HA7EBCD4899E244B7AAE43E3DE910182A"><enum>(8)</enum><text display-inline="yes-display-inline">Identify partner countries where advanced pharmaceutical ingredients and finished drug products could be manufactured to reduce dependence on China and other countries.</text></paragraph> <paragraph id="HDE9CB60C19AC4B378A45715C363CE7A0" commented="no"><enum>(9)</enum><text display-inline="yes-display-inline">Provide recommendations on legislative and regulatory actions that can be taken to address vulnerabilities in the United States pharmaceutical supply chain and increase the number of manufacturers of advanced pharmaceutical ingredients and finished drug products in the United States.</text></paragraph> 
<paragraph id="H60C1789B03904A2F84323F2BBC517898"><enum>(10)</enum><text display-inline="yes-display-inline">Identify and propose steps that can be taken to increase coordination among different Federal and State programs to increase manufacturing of domestic advanced pharmaceutical ingredients and finished drug products.</text></paragraph></subsection> <subsection id="HDD45B4D66F3E43CEA8ED0AC4A8F7BEDC"><enum>(c)</enum><header>Membership</header> <paragraph id="H403E3D17D6FA4C1DBF1CFB575A3F2A72"><enum>(1)</enum><header>In general</header><text>The Commission shall be composed of at least 6 but not more than 11 members as follows:</text> 
<subparagraph id="H8BF6CB11521C46D68032AF128BFCA9A2"><enum>(A)</enum><text display-inline="yes-display-inline">The National Security Advisor, who shall serve as co-chair.</text></subparagraph> <subparagraph id="HDE587A4FF16C4BEF9BE58B64C4726187"><enum>(B)</enum><text display-inline="yes-display-inline">The White House Domestic Policy Council, who shall serve as co-chair.</text></subparagraph> 
<subparagraph id="H454C42124FDC48BCAAA8164CE8B59E79"><enum>(C)</enum><text>The Secretary of Health and Human Services.</text></subparagraph> <subparagraph id="H0C7DA83092FE40378B79220ADF9DB5BF"><enum>(D)</enum><text display-inline="yes-display-inline">The Secretary of Defense.</text></subparagraph> 
<subparagraph id="H38868A8714474AEA8C698C59A320D407"><enum>(E)</enum><text display-inline="yes-display-inline">The Secretary of State.</text></subparagraph> <subparagraph id="HF0CD13F2819F46288B92C96E7E14E629"><enum>(F)</enum><text display-inline="yes-display-inline">The Secretary of Commerce.</text></subparagraph> 
<subparagraph id="H5D6DB9B476C24B178C50AFD49F331DCD"><enum>(G)</enum><text display-inline="yes-display-inline">Not more than 5 members as may be appointed by joint action of the co-chairs of the Commission, from among the employees and officers of appropriate Federal departments and agencies.</text></subparagraph></paragraph> <paragraph id="H9508D0792D014F5184C676779FF98C7A"><enum>(2)</enum><header>Terms</header><text>Each member shall be appointed for the life of the Commission.</text></paragraph> 
<paragraph id="H812F7C114A7147CFAF698D9BE71604C9"><enum>(3)</enum><header>Quorum</header><text>A majority of the Commission shall constitute a quorum but a lesser number may hold hearings.</text></paragraph></subsection> <subsection id="H3A9B12C782714F3690081BC8731CE080"><enum>(d)</enum><header>Powers of Commission</header><text>The Commission may, for the purpose of carrying out this Act, hold hearings, sit and act at times and places, take testimony, and receive evidence as the Commission considers appropriate.</text></subsection> 
<subsection id="HC6BF3EF391C746CDA738EA0AB8E68C7B"><enum>(e)</enum><header>Reports</header> 
<paragraph id="HDAF38CA9BC384F059800749D3E4443EF"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, and annually thereafter until the date of the termination of the Commission under subsection (f), the Commission shall submit to Congress a report detailing the findings, conclusions, and recommendations of the Commission in fulfilling its duties under subsection (b).</text> </paragraph> <paragraph id="HEADF0DAF3DB843309BE9B0E9753D1E4B"><enum>(2)</enum><header>Form of reports</header><text>The reports described in paragraph (1) shall be submitted in unclassified form but may include a classified annex.</text></paragraph></subsection> 
<subsection id="HC8E8D282A27B49F0B521211002F7EFD6" commented="no"><enum>(f)</enum><header>Termination</header><text>The Commission shall terminate on the date that is 4 years after the date of enactment of this Act.</text> </subsection> <subsection id="H8E029DF606D647F7A791F52C7C03CA04"><enum>(g)</enum><header>Essential medicines list defined</header> <text>In this section, the term <term>essential medicines list</term> means the list of the Food and Drug Administration described in section 3(c) of Executive Order 13944.</text> </subsection></section> 
</legis-body></bill>

